Anthrax vaccine efficacy in golden Syrian hamsters

The efficacy of a licensed human anthrax vaccine (anthrax vaccine adsorbed, AVA) was tested in golden Syrian hamsters against a virulent Bacillus anthracis spore challenge. Groups of golden Syrian hamsters were vaccinated at either 0 and 4 weeks or 0, 4 and 8 weeks, then challenged subcutaneously (s...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2002-01, Vol.20 (9), p.1421-1424
Main Authors: Fellows, P.F, Linscott, M.K, Little, S.F, Gibbs, P, Ivins, B.E
Format: Article
Language:English
Subjects:
Animals
Anthrax
Anthrax Vaccines - immunology
Antibodies, Bacterial - blood
Bacillus anthracis
Biological and medical sciences
Cricetinae
Enzyme-Linked Immunosorbent Assay
Epidemiology. Vaccinations
Fundamental and applied biological sciences. Psychology
General aspects
Hamster
Immunization
Infectious diseases
Male
Medical sciences
Mesocricetus
Models, Animal
Protozoa
Vaccine
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The efficacy of a licensed human anthrax vaccine (anthrax vaccine adsorbed, AVA) was tested in golden Syrian hamsters against a virulent Bacillus anthracis spore challenge. Groups of golden Syrian hamsters were vaccinated at either 0 and 4 weeks or 0, 4 and 8 weeks, then challenged subcutaneously (s.c.) at 10 weeks with spores of various B. anthracis isolates. Although ELISA and toxin neutralization assays demonstrated high titers, none of the AVA-vaccinated hamsters were protected from challenge or demonstrated a significantly extended time to death compared to that of control animals. The results of the study demonstrate that the golden Syrian hamster is not an appropriate model for investigating human anthrax vaccine efficacy.
ISSN:0264-410X
1873-2518
DOI:10.1016/S0264-410X(01)00461-3